Case-Fatality Rates and Sequelae Resulting from Neisseria meningitidis Serogroup C Epidemic, Niger, 2015
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i


Case-Fatality Rates and Sequelae Resulting from Neisseria meningitidis Serogroup C Epidemic, Niger, 2015
Filetype[PDF-1.39 MB]


Details:
No Related Documents.

You May Also Like:

  1. Personal Author:
    Sidikou, Fati ; Zaneidou, Maman ; ...
    Published Date:
    Aug 23 2016
    Source:
    Lancet Infect Dis. 16(11):1288-1294.
    Description:
    BackgroundTo combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate v...
    File Type:
    Filetype[PDF - 320.91 KB]
    File Type:
    Filetype[PDF - 320.91 KB]
  2. Personal Author:
    Collard, Jean-Marc ; Maman, Zaneidou ; ...
    Published Date:
    Sep 2010
    Source:
    Emerg Infect Dis. 16(9):1496-1498.
    File Type:
    Filetype[PDF - 116.28 KB]
    File Type:
    Filetype[PDF - 116.28 KB]
  3. Personal Author:
    Kretz, Cecilia B. ; Retchless, Adam C. ; ...
    Corporate Authors:
    Niger Response Team
    Published Date:
    Oct 2016
    Source:
    Emerg Infect Dis. 22(10):1762-1768.
    Description:
    In 2015, Niger reported the largest epidemic of Neisseria meningitidis serogroup C (NmC) meningitis in sub-Saharan Africa. The NmC epidemic coincided ...
    File Type:
    Filetype[PDF - 1.53 MB]
    File Type:
    Filetype[PDF - 1.53 MB]
  4. Personal Author:
    Maïnassara, Halima Boubacar ; Paireau, Juliette ; ...
    Published Date:
    Aug 2015
    Source:
    Emerg Infect Dis. 21(8):1322-1329.
    Description:
    To inform epidemic response strategies for the African meningitis belt after a meningococcal serogroup A conjugate vaccine was introduced in 2010, we ...
    File Type:
    Filetype[PDF - 1.90 MB]
    File Type:
    Filetype[PDF - 1.90 MB]
  5. Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    July 7, 2017
    Series:
    HAN ; 404
    Description:
    July 7, 2017, 11:00 ET (11:00 AM ET)CDCHAN-00404Summary: Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningo...
    File Type:
    Filetype[PDF - 52.97 KB]
    File Type:
    Filetype[PDF - 52.97 KB]